Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The ENERGY Study: An Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 in Infants With Ectonucleotide Pyrophosphatase/ Phosphodiesterase 1 (ENPP1) Deficiency or ATP-binding Cassette Sub-family C Member 6 (ABCC6) Deficiency

NCT05734196 is registered in ClinicalTrials.gov with Inozyme Pharma as lead sponsor.

NCT NCT05734196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05734196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The ENERGY Study: An Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 in Infants With Ectonucleotide Pyrophosphatase/ Phosphodiesterase 1 (ENPP1) Deficiency or ATP-binding Cassette Sub-family C Member 6 (ABCC6) Deficiency
Lead sponsor
Inozyme Pharma
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 25, 2023
Completion date
October 14, 2026
Enrollment
16 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

atp-binding cassette subfamily c member 6 deficiency, autosomal recessive hypophosphatemic rickets, ectonucleotide pyrophosphatase/phosphodiesterase1 deficiency, generalized arterial calcification of infancy, pseudoxanthoma elasticum